|
Dec 20
|
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
|
|
Dec 1
|
Calliditas announces additions to the management team
|
|
Nov 30
|
Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome
|
|
Nov 24
|
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy
|
|
Nov 7
|
Calliditas to present at upcoming investor conferences
|
|
Nov 7
|
Calliditas Interim Report January - September 2023
|
|
Nov 7
|
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023
|
|
Jul 6
|
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?
|